Clinical Trial Update: Efficacy and Safety of HAT1 Compared to Calcipotriol in Patients With Mild to Moderate Chronic Plaque Psoriasis [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing HAT1 to calcipotriol in mild-to-moderate chronic plaque psoriasis has completed and reports on efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis
• Psoriasis

Drugs mentioned

• Calcipotriol (calcipotriol)
• HAT1 (HAT1)

Snippet

Sponsor: Haus Bioceuticals | Conditions: Psoriasis | Phase 2 | Status: COMPLETED